Fate Therapeutics Inc. has entered into a sales agreement with Leerink Partners LLC, allowing the company to offer and sell shares of its common stock valued at up to $100 million. This strategic move, announced on November 5, 2026, is aimed at enhancing the company’s financial resources as it continues to develop its innovative cellular therapies.

The sales agreement will enable Fate to conduct an "at-the-market offering," meaning shares can be sold over time at prevailing market prices, providing flexibility in capital raising. The company’s common stock is traded on the Nasdaq under the ticker symbol "FATE," and as of November 4, 2026, the last reported sale price was $2.09 per share.

Background

Fate Therapeutics Inc., incorporated in 2007 and headquartered in San Diego, California, operates within the biological products sector, specifically focusing on the development of cellular immunotherapies. The company is classified under the SIC code 2836, which pertains to Biological Products (No Diagnostic Substances). Fate is recognized for its pioneering work in cellular programming, utilizing induced pluripotent stem cells (iPSCs) to create innovative therapies.

In recent filings, Fate has demonstrated a commitment to advancing its clinical programs, including the initiation of the Phase 2 clinical trial for FT819, aimed at treating systemic lupus erythematosus. The company has also received significant funding from the California Institute for Regenerative Medicine to support its clinical development efforts.

What the Filing Says

The filing states, "We may offer and sell shares of our common stock having an aggregate offering price of up to $100,000,000 from time to time through Leerink Partners, acting as sales agent." The agreement outlines that Leerink Partners will act as the sales agent, utilizing commercially reasonable efforts to sell the shares.

The sales agent will earn a commission of up to 3.0% on the gross proceeds from any shares sold under this agreement. Additionally, Fate has agreed to indemnify Leerink Partners against certain liabilities, including those arising under the Securities Act.

Impact

This capital-raising initiative may significantly affect various stakeholders, including investors looking for opportunities in the biopharmaceutical sector. The funds raised will likely support Fate's ongoing clinical trials and development of its product pipeline, potentially impacting patient access to innovative therapies.

Furthermore, this move could influence other companies in the biological products industry, encouraging them to pursue similar funding strategies to support their research and development efforts.

What's Next

The filing does not specify what happens next, but it indicates that Fate Therapeutics plans to continue offering shares under the terms of the sales agreement as market conditions allow. Investors and market watchers will be keen to see how the company utilizes the proceeds from this offering to advance its clinical programs and overall business objectives.